New Treatment in Advanced Thyroid Cancer

Giuffrida, Dario; Prestifilippo, Angela; Scarfia, Alessia; Martino, Daniela Di; Marchisotta, Stefania

doi:10.1155/2012/391629

Cited by 16 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thyroid carcinomas are generally poorly responsive to cytotoxic chemotherapy [ 39 – 42 ], which could be attributed to the presence of intracellular inhibitors of apoptotic signaling cascades. The present study showed that HDAC inhibitors induced pro-apoptotic proteins and reduced anti-apoptotic proteins, producing potent antitumor effects in the two thyroid cancer cell lines studied.…”

Section: Discussionmentioning

confidence: 99%

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer

et al. 2015

View full text Add to dashboard Cite

BackgroundThyroid cancer has been indicated to have a higher global proportion of DNA methylation and a decreased level of histone acetylation. Previous studies showed that histone gene reviser and epigenetic changes role significant parts in papillary and anaplastic thyroid cancer tumorigenesis. The goal of this research was to study the endoplasmic reticulum (ER) stress-mediated actions of the dominant histone deacetylase (HDAC) inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide (HNHA), in thyroid cancer and to explore its effects on apoptotic cell death pathways.MethodsExperiments were achieved to conclude the effects of HNHA in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC) cell lines and xenografts, as compared with two other established HDAC inhibitors (SAHA; suberoylanilide hydroxamic acid and TSA; trichostatin A).ResultsApoptosis, which was induced by all HDAC inhibitors, was particularly significant in HNHA-treated cells, where noticeable B-cell lymphoma-2 (Bcl-2) suppression and caspase activation were observed both in vitro and in vivo. HNHA increased Ca2+ release from the ER to the cytoplasm. ER stress-dependent apoptosis was induced by HNHA, suggesting that it induced caspase-dependent apoptotic cell death in PTC and ATC. PTC and ATC xenograft studies demonstrated that the antitumor and pro-apoptotic effects of HNHA were greater than those of the established HDAC inhibitors. These HNHA activities reflected its induction of caspase-dependent and ER stress-dependent apoptosis on thyroid cancer cells.ConclusionsThe present study indicated that HNHA possibly provide a new clinical approach to thyroid cancers, including ATC.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Reduced ADC values have been reported for most malignant tumors and are thought to be due to cellular membranes impeding the mobility of water protons [19,20]. In our study, there was a significant difference between the mean ADC value of benign and malignant nodules (P value < 0.0001), the mean ADC of the malignant thyroid nodules (15 nodules) was (0.71 ± 0.15 × 10 -3 mm 2 /s) while that of the benign thyroid nodules (58 nodules) was (1.7 ± 0.12 × 10 -3 mm 2 /s).…”

Section: Discussionmentioning

confidence: 99%

Can quantitative diffusion-weighted MR imaging differentiate between different subtypes of benign and malignant solitary thyroid nodules?

Abdelgawad

Abdel-Gawad

AbuElCebaa

et al. 2020

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background: Diffusion-weighted MR imaging (DWI) is sensitive to changes in the microstructural organization of tissue that may influence water diffusion. It has been utilized in various forms to evaluate head and neck tumors. The apparent diffusion coefficient (ADC) value is a quantitative parameter for distinguishing malignant from benign thyroid nodule. Determination of different pathologic types of the thyroid nodules is crucial for appropriate therapeutic approach. Our point was to assess the utility of apparent diffusion coefficient values in discriminating different subtypes of benign and malignant solitary thyroid nodules using diffusion MRI with pathological correlation. Results: This prospective study included 73 patients who had thyroid nodules. The size of the investigated lesions ranged from 0.6 to 3 cm. Most nodules were benign (79.45%), and most of these benign nodules were adenomatous nodules. There was a significant difference in ADC values of benign and malignant thyroid nodules (P 0.0001), with the mean ADC value for the benign group (1.7 ± 0.12 × 10-3) higher than that for malignant nodule (0.71 ± 0.15 × 10). The sensitivity, specificity, and accuracy of ADC in differentiating between benign and malignant thyroid nodules were 97.5, 94.4, and 99.2%, respectively. We noticed a significant overlap in the ADC value of pathological subtypes and upon reviewing the pathological results, we found insignificant differences in the ADC values of the various subtypes of malignant and benign nodules, with P value ranging from 0.054 to 0.062 between different pathological subtypes. A significant difference was only noted between non-complicated cysts and solid nodules P 0.0001. In our series, an ADC value of 0.92 × 10-3 mm 2 /s or less could be used as an indicator of malignancy, with a sensitivity of 97.5%, a specificity of 94.4%, and an accuracy of 99.2%. Conclusion: Diffusion MRI including ADC values are helpful in differentiation between benign and malignant thyroid nodules but not helpful in differentiating between different subtypes of benign and malignant nodules.

show abstract

“…In the last decade, the scientific community has made significant strides toward a better understanding of the biology of thyroid cancer, and this research has facilitated significant progress in the development of novel and more effective treatment modalities for advanced thyroid cancer [7,8] . Like most endocrine tumors, thyroid tumors are richly vascularized, and initial clinical studies exploited the important role of increased angiogenesis in thyroid cancer [9] .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer

Xie

Chen

et al. 2017

Acta Pharmacol Sin

View full text Add to dashboard Cite

Thyroid cancer is the most common type of endocrine neoplasia. Despite recent breakthroughs in treatment of the disease, the treatment of advanced, progressive thyroid cancers remains challenging with limited therapeutic options available. In this study, we evaluated a novel and orally bioavailable small-molecule multiple tyrosine kinases inhibitor, AL3810, in preclinical models of thyroid cancer in vitro and in vivo. AL3810 (2-5 μmol/L) dose-dependently inhibited the proliferation of human thyroid cancer cell lines TT, SW579 and TPC-1 in vitro with IC values ranging from 0.59 to 7.03 μmol/L. Specifically, this agent dose-dependently arrested the thyroid cancer cells in the G phase and induced apoptosis. Furthermore, AL3810 dose-dependently inhibited the migration and invasion of SW579 and TPC-1 cells in vitro. In SW579 and TT xenograft models, oral administration of AL3810 (5-20 mg·kg·d) for 21 d potently inhibited the tumor growth; immunohistochemical staining revealed that the antitumor activity of AL3810 was closely correlated with its anti-angiogenesis effect, as evidenced by a dose-dependent reduction of microvessels in tumor tissues. To assess the therapeutic potential of AL3810 in treating thyroid cancer involving RET gene fusion, we showed that AL3810 (1-10 μmol/L) dose-dependently inhibited the proliferation of RET-driven Baf3 cell line Baf3-CCDC6-RET, and the auto-phosphorylation of RET in these cells. Our data suggest that AL3810 is a promising agent for the treatment of thyroid cancer.

show abstract

New Treatment in Advanced Thyroid Cancer

Cited by 16 publications

References 49 publications

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer

Can quantitative diffusion-weighted MR imaging differentiate between different subtypes of benign and malignant solitary thyroid nodules?

Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer

Contact Info

Product

Resources

About